OGFRL1缺陷通过病理性破骨细胞生成导致慢性复发性多灶性骨髓炎,且对肿瘤坏死因子抑制剂治疗有反应
研究验证了一例慢性复发性多灶性骨髓炎(CRMO)患者中OGFRL1功能缺失变异(c.30del, p.F10Ffs*110)的致病性及机制。患者炎症通路激活、髓系细胞活化,Ogfrl1敲除小鼠关节炎和骨侵蚀更重、破骨细胞分化增强,患者对TNF抑制剂治疗反应良好。
要点
- OGFRL1功能缺失变异是CRMO的新型致病原因。
- OGFRL1缺陷通过促进破骨细胞分化导致骨侵蚀。
- TNF抑制剂可改善该患者的炎症指标和骨溶解病变。
核心结论
- OGFRL1缺陷是CRMO的新型致病原因,OGFRL1具有抑制炎症反应的作用。
研究设计与样本
- 对一例携带OGFRL1变异(c.30del, p.F10Ffs*110)的CRMO患者进行全外显子测序和Sanger测序验证。
- 对比患者与健康对照的炎症特征,采用qPCR、ELISA、细胞珠检测、批量RNA测序和单细胞RNA测序。
- 在Ogfrl1敲除和野生型小鼠中建立胶原抗体诱导关节炎(CAIA)模型,并进行micro-CT扫描。
- 体外进行破骨细胞诱导和分化实验以探索机制。
主要发现
- 患者MAPK和NF-κB信号通路上调,促炎细胞因子过度产生。
- 患者髓系细胞明显活化,尤其是单核细胞、树突状细胞和低密度粒细胞(LDGs)。
- CAIA模型中Ogfrl1敲除小鼠较野生型小鼠发生更严重且持续的关节炎和骨侵蚀。
- Ogfrl1敲除小鼠比野生型小鼠更易发生破骨细胞分化。
- 患者对TNF抑制剂治疗反应良好,C反应蛋白、红细胞沉降率、血清淀粉样蛋白A和白细胞介素-6水平正常化,骨溶解病变改善。
关键数值与推荐
- 患者OGFRL1变异为c.30del, p.F10Ffs*110。
- 患者经TNF抑制剂治疗后CRP、ESR、SAA和IL-6水平正常化,骨溶解病变改善。
临床怎么用
- 对CRMO患者可考虑筛查OGFRL1功能缺失变异。
- 携带OGFRL1缺陷的CRMO患者可能从TNF抑制剂治疗中获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To verify the pathogenesis of the opioid growth factor receptor like-1 (OGFRL1) loss-of-function variant (c.30del, p. F10Ffs*110) identified in a patient with chronic recurrent multifocal osteomyelitis (CRMO) and to investigate the underlying mechanism. METHODS: Whole exome sequencing and Sanger sequencing were performed to identify and confirm the variant. Quantitative polymerase chain reaction, enzyme-linked immunosorbent assay, cytometric bead assay, bulk RNA sequencing, and single-cell RNA sequencing were conducted to detect the inflammatory signatures of the patient versus healthy controls. A collagen antibody-induced arthritis (CAIA) model was generated in Ogfrl1 knockout (KO) and wild type (WT) mice, and micro-computed tomography scan was performed to investigate the pathogenicity of Ogfrl1 deficiency. In addition, osteoclast induction and differentiation in vitro was exerted to explore the underlying mechanism of Ogfrl1 deficiency. RESULTS: The patient exhibited up-regulated mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways, along with overproduction of pro-inflammatory cytokines. Compared to healthy controls, apparent activation of myeloid cells was observed, especially in monocytes, dendritic cells, and low-density granulocytes (LDGs) of the patient. In the CAIA model, Ogfrl1 KO mice developed more severe and persistent arthritis and bone erosion than WT mice. Ogfrl1 KO mice were more prone to osteoclast differentiation than WT mice. The patient responded well to tumor necrosis factor inhibitor therapy, with normalization of C-reactive protein levels, erythrocyte sedimentation rate, serum amyloid A levels, and interleukin-6 levels, as well as improvement in osteolytic lesions. CONCLUSION: This study identified OGFRL1 deficiency as a novel cause of CRMO, highlighted the previously unrecognized role of OGFRL1 in restraining inflammatory responses, and provided novel insights into the pathogenesis and treatment of this autoinflammatory disorder.
引用
- Xiong W, Wang Y, He T, et al. OGFRL1 Deficiency Causes Chronic Recurrent Multifocal Osteomyelitis Via Pathologic Osteoclastogenesis, With Therapeutic Response to Tumor Necrosis Factor Inhibitor. Arthritis Rheumatol. 2026. PMID: 41568604. doi:10.1002/art.70057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。